MI Cancer Seek® Companion Diagnostic Molecular Profiling Test for Solid Tumors
MI Cancer Seek is a next-generation sequencing (NGS) based in vitro diagnostic (IVD) device using total nucleic acid (TNA) isolated from formalin-fixed paraffin-embedded (FFPE) tumor tissue specimens for the detection of single nucleotide variants (SNVs) and insertions and deletions (indels) in 228 genes, microsatellite instability (MSI), tumor mutational burden (TMB) in patients with previously diagnosed solid tumors, and copy number amplification (CNA) in one gene in patients with breast cancer. MI Cancer Seek® is the first and only simultaneous Whole Exome Sequencing (WES) and Whole Transcriptome Sequencing (WTS)-based assay with FDA-approved CDx indications for molecular profiling of solid tumors.
MI Cancer Seek is intended as a companion diagnostic to identify patients who may benefit from treatment with the targeted therapies listed in the Companion Diagnostic Indications table, in accordance with the approved therapeutic product labeling. Additionally, MI Cancer Seek is intended to provide tumor mutational profiling to be used by qualified healthcare professionals in accordance with professional oncology guidelines for cancer patients with previously diagnosed solid malignant neoplasms. Genomic findings other than those listed in the Companion Diagnostic Indications table are not prescriptive or conclusive for labeled use of any specific therapeutic product.
| Indication | Biomarker | Therapy |
|---|---|---|
| Breast Cancer | PIK3CA (C420R; E542K; E545A; E545D [1635G>T only]; E545G; E545K; Q546E; Q546R; H1047L; H1047R; H1047Y) | PIQRAY® (alpelisib) |
| Colorectal Cancer (CRC) | KRAS wild-type (no mutations in exons 2, 3, 4) and NRAS wild-type (no mutations in exons 2, 3, 4) | VECTIBIX® (panitumumab) |
| Colorectal Cancer (CRC) | BRAF V600E | BRAFTOVI® (encorafenib) + ERBITUX® (cetuximab) |
| Melanoma | BRAF V600E | BRAF inhibitors (FDA-approved)* |
| Melanoma | BRAF V600E or V600K | MEKINIST® (trametinib) or FDA-approved **BRAF/MEK inhibitor combinations*** |
| Non-Small Cell Lung Cancer (NSCLC) | EGFR exon 19 deletions or exon 21 L858R alterations | **FDA-approved EGFR tyrosine kinase inhibitors*** |
| Solid Tumors | MSI-H | KEYTRUDA® (pembrolizumab), JEMPERLI® (dostarlimab-gxly) |
| Endometrial Carcinoma (Not MSI-H) | Not MSI-H | KEYTRUDA® (pembrolizumab) + LENVIMA® (lenvatinib) |
This test is provided by Caris Life Sciences, https://www.carislifesciences.com/physicians/physician-tests/mi-cancer-seek/
- Companion diagnostic (CDx) to identify patients who may benefit from cancer treatment with the targeted therapies as shown in the table above
- To provide tumor mutational profiling to be used in accordance with professional oncology guidelines for cancer patients with previously diagnosed solid tumors
Positive: A clinically significant genomic alteration or biomarker is detected that may inform targeted therapy, immunotherapy, or trial selection.
Negative: No actionable genomic alterations detected. Absence of detected biomarkers does not exclude the presence of subclonal, low-frequency, or non-covered alterations.
Results must be interpreted in conjunction with clinical, radiologic, and histopathologic findings.
Not applicable (qualitative companion diagnostic assay)
FFPE tumor tissue (biopsy or resection block or unstained slides).
Stability
Room temperature for longer period.
- Oncotarget. 2025 Aug 13:16:642-659. [PMID: 40804002]
- Sci Rep. 2025 Jul 1;15(1):21173. [PMID: 40596693]
- JCO Precis Oncol. 2024 Oct:8:e2300648. [PMID: 39565978]
- Nature. 2024 Dec;636(8043):728-736. [PMID: 39506116]